SUZHOU, China, April 10, 2024 /PRNewswire/ -- IBD, or Inflammatory Bowel Disease, traditionally more prevalent in developed nations, is increasingly observed in developing regions like China. It is a chronic, nonspecific inflammatory gastrointestinal disorder with an unknown etiology, characterized by symptoms such as abdominal pain, diarrhea, fever, and bloody stool.

中国苏州，2024年4月10日/PRNewswire/--炎症性肠病（IBD）在发达国家传统上更为普遍，在中国等发展中地区越来越多地被观察到。它是一种病因不明的慢性非特异性炎症性胃肠道疾病，其特征是腹痛，腹泻，发烧和血便等症状。

However, treatment options remain limited, focusing primarily on managing complications and promoting inflammatory wound healing to enhance patients' quality of life. With its high recurrence rate, there is a pressing need for effective drug development to address the unmet medical needs associated with IBD..

然而，治疗选择仍然有限，主要集中在管理并发症和促进炎性伤口愈合以提高患者的生活质量。由于其高复发率，迫切需要有效的药物开发来解决与IBD相关的未满足的医疗需求。。

Mesenchymal stem cells (MSCs) are pluripotent stem cells capable of modulating immune cells in their microenvironment through the secretion of growth factors, chemokines, and extracellular vesicles (EVs). Numerous reports highlight the therapeutic potential and clinical efficacy of MSC-EVs in various conditions, including osteoarthritis, pulmonary fibrosis, autoimmune diseases, and organ transplantation.

间充质干细胞（MSCs）是多能干细胞，能够通过分泌生长因子，趋化因子和细胞外囊泡（EVs）来调节其微环境中的免疫细胞。许多报道强调了MSC-EVs在各种情况下的治疗潜力和临床疗效，包括骨关节炎，肺纤维化，自身免疫性疾病和器官移植。

Leveraging the advantages of EVs—such as biocompatibility, low immunogenicity, enhanced safety, efficient drug delivery, and long-term storage—MSC-EVs hold promise for therapeutic applications in IBD..

利用电动汽车的优点，例如生物相容性，低免疫原性，增强的安全性，有效的药物递送和长期储存MSC电动汽车有望在IBD中进行治疗应用。。

Recent research by VesiCURE Therapeutics, published in BioRxiv, entitled 'Mesenchymal stem cell-derived extracellular vehicles attenuate symptoms in dextran sulfate-induced ulcerative colitis mouse model'(DOI: https://doi.org/10.1101/2024.02.01.578325), demonstrates the effectiveness of MSC-EVs in treating iBD in a mouse model of ulcerative colitis induced by dextran sulfate.

VesiCURE Therapeutics最近的研究发表在BioRxiv上，题为“间充质干细胞衍生的细胞外载体减轻硫酸葡聚糖诱导的溃疡性结肠炎小鼠模型的症状”（DOI：https://doi.org/10.1101/2024.02.01.578325)，证明了MSC-EVs在硫酸葡聚糖诱导的溃疡性结肠炎小鼠模型中治疗iBD的有效性。

The study reveals significant alleviation of symptoms, including weight loss, diarrhea, and occult blood in stools. Furthermore, at the cellular level, MSC-EV administration restores mucosal integrity and reduces immune cell infiltration in the submucosa of iBD model mice. As a pioneer in exosome therapy, VesiCURE is dedicated to advancing EV-based drug development to create accessible and efficient therapeutic solutions for patients worldwide..

该研究显示，症状显着缓解，包括体重减轻，腹泻和大便隐血。此外，在细胞水平上，MSC-EV给药恢复粘膜完整性并减少iBD模型小鼠粘膜下层的免疫细胞浸润。作为外泌体治疗的先驱，VesiCURE致力于推进基于EV的药物开发，为全球患者创造可获得且有效的治疗方案。。

Media Contact: vesicure@vesicure.com

媒体联系人：vesicure@vesicure.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/development-of-exosome-therapy-to-treat-inflammatory-bowel-disease-by-vesicure-therapeutics-302112649.html

查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/development-of-exosome-therapy-to-treat-inflammatory-bowel-disease-by-vesicure-therapeutics-302112649.html

SOURCE VesiCURE Therapeutics Co.Ltd

SOURCE VesiCURE治疗有限公司